Pharmaceutical Company Sponsors

This meeting is supported by:

Gilead

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.

All Sponsors Logos Pfizer v2-05.png

FUNGAL UPDATE 2018 – Word from our Sponsor

Today, Pfizer UK offers patients access to a diverse portfolio of over 20 antibacterial and antifungal medicines.

More than ever, the world needs new approaches to preventing and fighting infections. Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of channels, including medical symposia, to ensure appropriate utilisation of antifungals and improve infection prevention and control.

Pfizer is proud to sponsor Fungal Update 2018 and we look forward to welcoming you to Fungal Update and sharing our activities with you.

PP-CRB-GBR-0141 Date of preparation: March 2018

MSD

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on TwitterLinkedIn and YouTube.#

F2G logomaster fungal 2018.jpg

F2G is a UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections.  F2G has discovered and developed a new class of antifungal agents called the orotomides, active against Aspergillus and other rare and resistant moulds. The orotomide class acts via a completely different mechanism than currently marketed antifungal agents and are active against many fungal infections resistant to current therapies. Olorofim (formerly F901318) is the lead compound and is available in both IV and oral presentations. Phase II clinical trials will start in early 2018 with pivotal registration trials to follow.

pulmocide-Logo fungal.jpg

Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Pulmocide’s innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects. The team has particular expertise in the identification of compounds with optimal characteristics for lung delivery.

Diagnostic Company Sponsors

This meeting is supported by:

Bruker

For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.  Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.  In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology and molecular pathology research.  For more information, please visit: www.bruker.com“   

Fungitell_Logo_PMS354_061517.jpg

Associates of Cape Cod, Inc. (ACC) has been a leader in endotoxin and (1→3)-ß-D-glucans detection products and services for more than 40 years.

Associates of Cape Cod, Inc. (ACC) manufacture and supply Fungitell®, the Gold Standard in Rapid Screening For Invasive Fungal Infection (IFI). Fungitell® is the first and the only FDA-cleared and CE marked rapid in vitro diagnostic screening test for IFI (including Candida, Aspergillus and Pneumocystis) that detects (1→3)-β-D-Glucan in serum. Fungitell is cleared for sales and marketing by the regulatory agencies of the European Union.

OLM fungal 2018.jpg

OLM Diagnostics is a medical diagnostics company, which develops and markets innovations in fungal and bacterial diagnostics to the healthcare sector. Our novel and reliable rapid-diagnostic tests fit seamlessly into current treatment pathways and can reduce the rate of drug resistant infections by promoting a new diagnostic led approach. This is achieved, whilst delivering clear financial and clinical benefits to hospitals, clinicians and patient care. 

IMMY_pantone Fungal Update 2018.jpg

IMMY focuses primarily on manufacturing rapid, high-quality fungal diagnostics. We manufacture products for cryptococcus, histoplasma, coccidioides, aspergillus, and blastomyces, along with mycobacteria specimen preparation reagents. IMMY is working to provide clear results for health professionals worldwide through accurate and affordable diagnostics for infectious diseases. 

The meeting is also supported by sponsorship from:

The meeting is endorsed by: